retatrutide triple agonist gip glp-1 glucagon phase 3 2025 First data, a Triumph of Science! From Obesity to Metabolic Health:
Description
Thirteen state Medicaid programs are covering GLP-1 drugs for the treatment of obesity this year, down from 16 last year.
Despite effectiveness, side effects like nausea and diarrhea are common, and most Americans say they dont plan to take them.
The convergence of chronic inflammation, mitochondrial dysfunction and altered protein metabolism makes individuals with metabolic diseases particularly vulnerable to sarcopenia
The study demonstrates that quantitative target engagement of dual agonists can be assessed by PET.
Not intended to replace lifestyle habits
Explore the potential benefits and risks of GLP-1 medications for people with inflammatory bowel dis
